Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly broke ground on a $6.5 billion Houston manufacturing facility, expected to begin operating in 2030, to produce Foundayo's active ingredient and other small-molecule medicines. CEO Dave Ricks said Foundayo accounts for one-third of new GLP-1 pill patients; the obesity drug generated $98 million in Q2 sales after its April U.S. launch. The investment is part of Lilly's more than $50 billion manufacturing expansion since 2020, aimed at meeting growing obesity and diabetes drug demand and competing with Novo.

Analysis

The relevant signal is oral-GLP-1 share capture, not the Houston buildout: a $98M first full quarter annualizes to only about $0.4B before launch-curve effects, so the equity upside requires rapid conversion of trial/early-adopter demand into reimbursed chronic use. Medicare coverage can broaden the addressable pool, but it also raises gross-to-net and formulary risk; the key read-through is net sales per prescription and persistence, not prescription starts. Lilly's reported share of new pill patients is directionally supportive but remains a company-sourced metric until corroborated by IQVIA/Symphony prescription data.

The plant has little bearing on 2026-28 supply and should not command an immediate valuation premium. Its more material effect is strategic: if oral therapy demand becomes a multi-product category, small-molecule capacity reduces dependence on constrained injectable fill-finish networks and can improve launch reliability across Lilly's pipeline. Conversely, the large committed manufacturing program creates depreciation, start-up expense and capital-intensity drag well before incremental revenue; investors should watch whether incremental obesity revenue continues to outpace capex and D&A growth.

Competitive pressure on NVO is likely to show first in payer negotiations rather than headline market share. A credible oral alternative gives PBMs leverage to demand deeper rebates from both companies, potentially limiting industry margin expansion even while patient volume rises. The contrarian view is that consensus may over-credit a single early share statistic: oral adherence, discontinuation, GI tolerability and Medicare prior-authorization rules could make the category less profitable than injectable revenue per patient, despite much larger access.

Key Decisions for Investors

• Maintain a 3-6 month long LLY / short NVO relative-value bias only after independent weekly prescription data confirms Lilly oral share above 25% for 6-8 consecutive weeks; target a 10-15% relative move, with exit if share falls below 15% or either company guides to materially higher obesity gross-to-net deductions.
• Do not add LLY exposure solely on the manufacturing announcement: the capacity contribution is outside the investable 12-24 month earnings window, while pre-revenue capex raises downside sensitivity if obesity growth decelerates.
• For LLY holders, use the next two earnings reports as the catalyst window and require oral-drug net sales to grow sequentially by at least 50% while management maintains obesity margin guidance; failure on either metric would falsify the near-term share-gain thesis.
• Monitor PBM formulary announcements and Medicare utilization-management rules over the next 1-3 months. Prefer reducing gross GLP-1 exposure if access expands but both LLY and NVO begin citing rebate pressure, as category volume growth may then translate into weaker-than-expected operating leverage.